Genetic Characterization Conferred Co-Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis Isolates from Southern Xinjiang, China

References

• Bagcchi S. WHO’s global tuberculosis report 2022. Lancet Microbe. 2023;4:e20. doi:10.1016/S2666-5247(22)00359-7
   PubMedGoogle Scholar
• Green KD, Garneau-Tsodikova S. Resistance in tuberculosis: what do we know and where can we go? Front Microbiol. 2013;4:208. doi:10.3389/fmicb.2013.00208
   PubMed Web of Science ®Google Scholar
• Tahaoglu K, Torun T, Sevim T, et al. The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med. 2001;345:170–174. doi:10.1056/NEJM200107193450303
   PubMed Web of Science ®Google Scholar
• World Health Organization. Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis: 2011 Update. Geneva: World Health Organization; 2011.
   Google Scholar
• Zhang Y, Heym B, Allen B, et al. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature. 1992;358:591–593. doi:10.1038/358591a0
   PubMed Web of Science ®Google Scholar
• Baulard AR, Betts JC, Engohang-Ndong J, et al. Activation of the pro-drug ethionamide is regulated in mycobacteria. J Biol Chem. 2000;275:28326–28331. doi:10.1074/jbc.M003744200
   PubMed Web of Science ®Google Scholar
• Vannelli TA, Dykman A, Ortiz de Montellano PR. The antituberculosis drug ethionamide is activated by a flavoprotein monooxygenase. J Biol Chem. 2002;277:12824–12829. doi:10.1074/jbc.M110751200
   PubMed Web of Science ®Google Scholar
• Banerjee A, Dubnau E, Quemard A, et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science. 1994;263:227–230. doi:10.1126/science.8284673
   PubMed Web of Science ®Google Scholar
• Vilcheze C, Wang F, Arai M, et al. Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid. Nat Med. 2006;12:1027–1029. doi:10.1038/nm1466
   PubMed Web of Science ®Google Scholar
• Vilcheze C, Morbidoni HR, Weisbrod TR, et al. Inactivation of the inhA-encoded fatty acid synthase II (FASII) enoyl-acyl carrier protein reductase induces accumulation of the FASI end products and cell lysis of Mycobacterium smegmatis. J Bacteriol. 2000;182:4059–4067. doi:10.1128/JB.182.14.4059-4067.2000
   PubMed Web of Science ®Google Scholar
• Vilcheze C, Jacobs WR, Hatfull GF, Jacobs Jr. WR. Resistance to isoniazid and ethionamide in Mycobacterium tuberculosis: genes, mutations, and causalities. Microbiol Spectr. 2014;2(4):MGM2-0014–2013. doi:10.1128/microbiolspec.MGM2-0014-2013
   Google Scholar
• Vilcheze C, Weisbrod TR, Chen B, et al. Altered NADH/NAD+ ratio mediates coresistance to isoniazid and ethionamide in mycobacteria. Antimicrob Agents Chemother. 2005;49:708–720. doi:10.1128/AAC.49.2.708-720.2005
   PubMed Web of Science ®Google Scholar
• Lee AS, Teo AS, Wong SY. Novel mutations in ndh in isoniazid-resistant Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother. 2001;45:2157–2159. doi:10.1128/AAC.45.7.2157-2159.2001
   PubMed Web of Science ®Google Scholar
• Newton GL, Buchmeier N, Fahey RC. Biosynthesis and functions of mycothiol, the unique protective thiol of Actinobacteria. Microbiol Mol Biol Rev. 2008;72:471–494. doi:10.1128/MMBR.00008-08
   PubMed Web of Science ®Google Scholar
• Ng VH, Cox JS, Sousa AO, et al. Role of KatG catalase-peroxidase in mycobacterial pathogenesis: countering the phagocyte oxidative burst. Mol Microbiol. 2004;52(5):1291–1302. doi:10.1111/j.1365-2958.2004.04078.x
   PubMed Web of Science ®Google Scholar
• Engohang-Ndong J, Baillat D, Aumercier M, et al. EthR, a repressor of the TetR/CamR family implicated in ethionamide resistance in mycobacteria, octamerizes cooperatively on its operator. Mol Microbiol. 2004;51:175–188. doi:10.1046/j.1365-2958.2003.03809.x
   PubMed Web of Science ®Google Scholar
• Cole ST, Brosch R, Parkhill J, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature. 1998;393:537–544. doi:10.1038/31159
   PubMed Web of Science ®Google Scholar
• Satta G, Lipman M, Smith GP, et al. Mycobacterium tuberculosis and whole-genome sequencing: how close are we to unleashing its full potential? Clin Microbiol Infect. 2018;24(6):604–609. doi:10.1016/j.cmi.2017.10.030
   PubMed Web of Science ®Google Scholar
• Meehan CJ, Goig GA, Kohl TA, et al. Whole genome sequencing of Mycobacterium tuberculosis: current standards and open issues. Nat Rev Microbiol. 2019;17:533–545. doi:10.1038/s41579-019-0214-5
   PubMed Web of Science ®Google Scholar
• Malinga L, Brand J, Jansen van Rensburg C, et al. Investigation of isoniazid and ethionamide cross-resistance by whole genome sequencing and association with poor treatment outcomes of multidrug-resistant tuberculosis patients in South Africa. Int J Mycobacteriol. 2016;5(Suppl 1):S36–S37. doi:10.1016/j.ijmyco.2016.11.020
   PubMedGoogle Scholar
• Roa MB, Tablizo FA, Morado EKD, et al. Whole-genome sequencing and single nucleotide polymorphisms in multidrug-resistant clinical isolates of Mycobacterium tuberculosis from the Philippines. J Glob Antimicrob Resist. 2018;15:239–245. doi:10.1016/j.jgar.2018.08.009
   PubMed Web of Science ®Google Scholar
• Truden S, Sodja E, Zolnir-Dovc M, Sundaramurthy V. Drug-resistant tuberculosis on the balkan peninsula: determination of drug resistance mechanisms with xpert MTB/XDR and whole-genome sequencing analysis. Microbiol Spectr. 2023;11(2):e0276122. doi:10.1128/spectrum.02761-22
   PubMed Web of Science ®Google Scholar
• Welekidan LN, Yimer SA, Skjerve E, et al. Whole genome sequencing of drug resistant and drug susceptible Mycobacterium tuberculosis isolates from Tigray Region, Ethiopia. Front Microbiol. 2021;12:743198. doi:10.3389/fmicb.2021.743198
   PubMedGoogle Scholar
• He W, Tan Y, Liu C, et al. Drug-resistant characteristics, genetic diversity, and transmission dynamics of rifampicin-resistant Mycobacterium tuberculosis in Hunan, China, revealed by whole-genome sequencing. Microbiol Spectr. 2022;10:e0154321. doi:10.1128/spectrum.01543-21
   PubMed Web of Science ®Google Scholar
• Liu D, Huang F, Zhang G, et al. Whole-genome sequencing for surveillance of tuberculosis drug resistance and determination of resistance level in China. Clin Microbiol Infect. 2022;28:731e739–731 e715. doi:10.1016/j.cmi.2021.09.014
   Web of Science ®Google Scholar
• O’Grady J, Maeurer M, Mwaba P, et al. New and improved diagnostics for detection of drug-resistant pulmonary tuberculosis. Curr Opin Pulm Med. 2011;17:134–141. doi:10.1097/MCP.0b013e3283452346
   PubMed Web of Science ®Google Scholar
• Rueda J, Realpe T, Mejia GI, et al. Genotypic analysis of genes associated with independent resistance and cross-resistance to isoniazid and ethionamide in Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother. 2015;59:7805–7810. doi:10.1128/AAC.01028-15
   PubMedGoogle Scholar
• Machado D, Perdigao J, Ramos J, et al. High-level resistance to isoniazid and ethionamide in multidrug-resistant Mycobacterium tuberculosis of the Lisboa family is associated with inhA double mutations. J Antimicrob Chemother. 2013;68:1728–1732. doi:10.1093/jac/dkt090
   PubMed Web of Science ®Google Scholar
• Kigozi E, Kasule GW, Musisi K, et al. Prevalence and patterns of rifampicin and isoniazid resistance conferring mutations in Mycobacterium tuberculosis isolates from Uganda. PLoS One. 2018;13:e0198091. doi:10.1371/journal.pone.0198091
   PubMedGoogle Scholar
• van Soolingen D, de Haas PE, Hermans PW, et al. DNA fingerprinting of Mycobacterium tuberculosis. Methods Enzymol. 1994;235:196–205.
   PubMed Web of Science ®Google Scholar
• Kamerbeek J, Schouls L, Kolk A, et al. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J Clin Microbiol. 1997;35:907–914. doi:10.1128/jcm.35.4.907-914.1997
   PubMed Web of Science ®Google Scholar
• Islam MM, Tan Y, Hameed HMA, et al. Detection of novel mutations associated with independent resistance and cross-resistance to isoniazid and prothionamide in Mycobacterium tuberculosis clinical isolates. Clin Microbiol Infect. 2019;25:1041e1041–1041 e1047. doi:10.1016/j.cmi.2018.12.008
   Web of Science ®Google Scholar
• Brossier F, Veziris N, Truffot-Pernot C, et al. Molecular investigation of resistance to the antituberculous drug ethionamide in multidrug-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2011;55:355–360. doi:10.1128/AAC.01030-10
   PubMed Web of Science ®Google Scholar
• Walker TM, Miotto P, Koser CU, et al. The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: a genotypic analysis. Lancet Microbe. 2022;3:e265–e273. doi:10.1016/S2666-5247(21)00301-3
   PubMedGoogle Scholar
• Kiepiela P, Bishop KS, Smith AN, et al. Genomic mutations in the katG, inhA and aphC genes are useful for the prediction of isoniazid resistance in Mycobacterium tuberculosis isolates from Kwazulu Natal, South Africa. Tuber Lung Dis. 2000;80(1):47–56. doi:10.1054/tuld.1999.0231
   PubMedGoogle Scholar
• Mokrousov I, Narvskaya O, Otten T, et al. High prevalence of KatG Ser315Thr substitution among isoniazid-resistant mycobacterium tuberculosis clinical isolates from Northwestern Russia, 1996 to 2001. Antimicrob Agents Chemother. 2002;46(5):1417–1424. doi:10.1128/AAC.46.5.1417-1424.2002
   PubMed Web of Science ®Google Scholar
• Ferro BE, Garcia PK, Nieto LM, et al. Predictive value of molecular drug resistance testing of Mycobacterium tuberculosis isolates in Valle del Cauca, Colombia. J Clin Microbiol. 2013;51:2220–2224. doi:10.1128/JCM.00429-13
   PubMed Web of Science ®Google Scholar
• Garcia de Viedma D, Del Sol Diaz Infantes M, Lasala F, et al. New real-time PCR able to detect in a single tube multiple rifampin resistance mutations and high-level isoniazid resistance mutations in Mycobacterium tuberculosis. J Clin Microbiol. 2002;40:988–995. doi:10.1128/JCM.40.3.988-995.2002
   PubMed Web of Science ®Google Scholar
• Abe C, Kobayashi I, Mitarai S, et al. Biological and molecular characteristics of Mycobacterium tuberculosis clinical isolates with low-level resistance to isoniazid in Japan. J Clin Microbiol. 2008;46:2263–2268. doi:10.1128/JCM.00561-08
   PubMed Web of Science ®Google Scholar
• Zhao X, Yu H, Yu S, et al. Hydrogen peroxide-mediated isoniazid activation catalyzed by Mycobacterium tuberculosis catalase−peroxidase (KatG) and its S315T mutant. Biochemistry. 2006;45:4131–4140. doi:10.1021/bi051967o
   PubMed Web of Science ®Google Scholar
• Pym AS, Saint-Joanis B, Cole ST. Effect of katG mutations on the virulence of Mycobacterium tuberculosis and the implication for transmission in humans. Infect Immun. 2002;70:4955–4960. doi:10.1128/IAI.70.9.4955-4960.2002
   PubMed Web of Science ®Google Scholar
• van Soolingen D, de Haas PE, van Doorn HR, et al. Mutations at amino acid position 315 of the katG gene are associated with high-level resistance to isoniazid, other drug resistance, and successful transmission of Mycobacterium tuberculosis in the Netherlands. J Infect Dis. 2000;182:1788–1790. doi:10.1086/317598
   PubMed Web of Science ®Google Scholar
• Brossier F, Veziris N, Truffot-Pernot C, et al. Performance of the genotype MTBDR line probe assay for detection of resistance to rifampin and isoniazid in strains of mycobacterium tuberculosis with low- and high-level resistance. J Clin Microbiol. 2006;44:3659–3664. doi:10.1128/JCM.01054-06
   PubMed Web of Science ®Google Scholar
• Torres JN, Paul LV, Rodwell TC, et al. Novel katG mutations causing isoniazid resistance in clinical M. tuberculosis isolates. Emerg Microbes Infect. 2015;4:e42. doi:10.1038/emi.2015.42
   PubMed Web of Science ®Google Scholar
• Morlock GP, Metchock B, Sikes D, et al. ethA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother. 2003;47:3799–3805. doi:10.1128/AAC.47.12.3799-3805.2003
   PubMed Web of Science ®Google Scholar
• Casali N, Nikolayevskyy V, Balabanova Y, et al. Evolution and transmission of drug-resistant tuberculosis in a Russian population. Nat Genet. 2014;46:279–286. doi:10.1038/ng.2878
   PubMed Web of Science ®Google Scholar
• Bollela VR, Namburete EI, Feliciano CS, et al. Detection of katG and inhA mutations to guide isoniazid and ethionamide use for drug-resistant tuberculosis. Int J Tuberc Lung Dis. 2016;20(8):1099–1104. doi:10.5588/ijtld.15.0864
   PubMed Web of Science ®Google Scholar
• Louw GE, Warren RM, Gey van Pittius NC, et al. A balancing act: efflux/influx in mycobacterial drug resistance. Antimicrob Agents Chemother. 2009;53(8):3181–3189. doi:10.1128/AAC.01577-08
   PubMed Web of Science ®Google Scholar
• Vaziri F, Kohl TA, Ghajavand H, et al. Genetic diversity of multi- and extensively drug-resistant Mycobacterium tuberculosis isolates in the capital of Iran, revealed by whole-genome sequencing. J Clin Microbiol. 2019;57. doi:10.1128/JCM.01477-18
   PubMed Web of Science ®Google Scholar
• Zhang Z, Lu J, Wang Y, et al. Prevalence and molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates in China. Antimicrob Agents Chemother. 2014;58(1):364–369. doi:10.1128/AAC.01228-13
   PubMed Web of Science ®Google Scholar
• Penn-Nicholson A, Georghiou SB, Ciobanu N, et al. Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB/XDR assay: a cross-sectional multicentre diagnostic accuracy study. Lancet Infect Dis. 2022;22:242–249. doi:10.1016/S1473-3099(21)00452-7
   PubMed Web of Science ®Google Scholar
• Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010;363:1005–1015. doi:10.1056/NEJMoa0907847
   PubMed Web of Science ®Google Scholar
• Maitre T, Morel F, Brossier F, et al. How a PCR sequencing strategy can bring new data to improve the diagnosis of ethionamide resistance. Microorganisms. 2022;10(7):1436. doi:10.3390/microorganisms10071436
   PubMed Web of Science ®Google Scholar